文献速递慢病防控与筛查免疫规划

18岁以下人群SARS-CoV-2感染后30天以上新诊断糖尿病的风险——美国,2020年3月1日至2021年6月28日

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-14

CDC利用IQVIA和HealthVerity两个回顾性队列的医疗索赔数据,评估18岁以下人群在SARS-CoV-2急性感染30天后新诊断糖尿病(1型、2型或其他糖尿病)的风险。结果显示,COVID-19患者糖尿病发病率显著高于无COVID-19诊断者(IQVIA:HR=2.66,95%CI=1.98-3.56;HealthVerity:HR=1.31,95%CI=1.20-1.44),也高于大流行前非COVID-19急性呼吸道感染诊断者(IQVIA:HR=2.16,95%CI=1.64-2.86)。

要点

  • 18岁以下COVID-19患者糖尿病发病率显著高于无COVID-19诊断者(IQVIA HR=2.66,95%CI=1.98-3.56)。
  • HealthVerity数据中COVID-19患者糖尿病发病率亦显著高于无COVID-19诊断者(HR=1.31,95%CI=1.20-1.44)。
  • IQVIA数据中COVID-19患者糖尿病风险显著高于大流行前非COVID-19急性呼吸道感染诊断者(HR=2.16,95%CI=1.64-2.86)。

核心结论

  • 18岁以下COVID-19患者新诊断糖尿病的风险显著高于无COVID-19诊断者及大流行前非COVID-19急性呼吸道感染诊断者。
  • 观察到的糖尿病风险增加凸显了在该年龄组所有符合条件者中实施COVID-19预防策略(包括疫苗接种)以及慢性病预防和管理的重要性。
  • SARS-CoV-2导致新发糖尿病的机制可能复杂,且可能因1型和2型糖尿病而异;SARS-CoV-2感染后监测长期后果(包括新发糖尿病迹象)在该年龄组很重要。

研究设计与样本

  • CDC利用IQVIA医疗索赔数据(2020年3月1日至2021年2月26日)构建回顾性队列,评估18岁以下患者COVID-19诊断后30天以上新诊断糖尿病(1型、2型或其他糖尿病)的发病率。
  • 比较对象为按年龄和性别匹配的1)大流行期间未接受COVID-19诊断的患者,或2)大流行前接受非COVID-19急性呼吸道感染诊断的患者。
  • 分析使用第二数据源HealthVerity(2020年3月1日至2021年6月28日)进行重复,该数据源包括有任何可能与COVID-19相关的医疗就诊的患者。

主要发现

  • IQVIA数据库中,COVID-19患者糖尿病发病率显著高于无COVID-19诊断者(HR=2.66,95%CI=1.98-3.56)。
  • HealthVerity数据库中,COVID-19患者糖尿病发病率显著高于无COVID-19诊断者(HR=1.31,95%CI=1.20-1.44)。
  • IQVIA数据库中,COVID-19患者糖尿病发病率显著高于大流行前非COVID-19急性呼吸道感染诊断者(HR=2.16,95%CI=1.64-2.86)。

临床怎么用

  • 原文结论指出,观察到的糖尿病风险增加凸显了在该年龄组所有符合条件者中实施COVID-19预防策略(包括疫苗接种)以及慢性病预防和管理的重要性。
  • 原文结论指出,SARS-CoV-2感染后监测长期后果(包括新发糖尿病迹象)在该年龄组很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic has disproportionately affected people with diabetes, who are at increased risk of severe COVID-19.* Increases in the number of type 1 diabetes diagnoses (1,2) and increased frequency and severity of diabetic ketoacidosis (DKA) at the time of diabetes diagnosis (3) have been reported in European pediatric populations during the COVID-19 pandemic. In adults, diabetes might be a long-term consequence of SARS-CoV-2 infection (4-7). To evaluate the risk for any new diabetes diagnosis (type 1, type 2, or other diabetes) >30 days† after acute infection with SARS-CoV-2 (the virus that causes COVID-19), CDC estimated diabetes incidence among patients aged <18 years (patients) with diagnosed COVID-19 from retrospective cohorts constructed using IQVIA health care claims data from March 1, 2020, through February 26, 2021, and compared it with incidence among patients matched by age and sex 1) who did not receive a COVID-19 diagnosis during the pandemic, or 2) who received a prepandemic non-COVID-19 acute respiratory infection (ARI) diagnosis. Analyses were replicated using a second data source (HealthVerity; March 1, 2020-June 28, 2021) that included patients who had any health care encounter possibly related to COVID-19. Among these patients, diabetes incidence was significantly higher among those with COVID-19 than among those 1) without COVID-19 in both databases (IQVIA: hazard ratio [HR] = 2.66, 95% CI = 1.98-3.56; HealthVerity: HR = 1.31, 95% CI = 1.20-1.44) and 2) with non-COVID-19 ARI in the prepandemic period (IQVIA, HR = 2.16, 95% CI = 1.64-2.86). The observed increased risk for diabetes among persons aged <18 years who had COVID-19 highlights the importance of COVID-19 prevention strategies, including vaccination, for all eligible persons in this age group,§ in addition to chronic disease prevention and management. The mechanism of how SARS-CoV-2 might lead to incident diabetes is likely complex and could differ by type 1 and type 2 diabetes. Monitoring for long-term consequences, including signs of new diabetes, following SARS-CoV-2 infection is important in this age group.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35025851. doi:10.15585/mmwr.mm7102e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。